Xlife Sciences AG (SIX: XLS) announces that its shareholders approved all motions on the agenda of the Ordinary Annual General Meeting (AGM) 2023 that took place earlier today in Zurich. A total of 3'289'495 voting shares, representing 61.6% of the whole share capital, were represented at this AGM.

David L. Deck, newly elected Chairman of the Board of Directors of Xlife Sciences, commented: “We thank all our shareholders for their trust in our Company. At the same time, we would like to thank our resigned Chairman Bernhard Scholz once again for his valuable contributions to the benefit of Xlife Sciences over the past four years”.

Oliver R. Baumann, CEO and member of the Board of Directors of Xlife Sciences, added: “The Board of Directors and the Management Team as well as all employees of our 26 project companies continue to be dedicated to creating value for all stakeholders of Xlife. Our progress achieved in H1 2023 includes, among others, the obtaining of a significant EU patent for Axenoll’s process to generate biological tissue, the receipt of the US approval for saniva diagnostics screening device NeuroMex, and the sale of around 45% of Xlife’s stake in Laxxon Medical. Upcoming reporting milestones will be the publication of our ESG 2022 report and our Half Year 2023 report in Q3 2023”.

Financial calendar

Half-Year Report 2023             September 21, 2023

Contact

Information for journalists: IRF Reputation AG, Valentin Handschin,

Information for investors: Xlife Sciences AG, Carl v. Halem,

Xlife Sciences AG
Talacker 35
8001 Zurich
Switzerland
Phone 0
,
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange

About Xlife Sciences AG (SIX: XLS) 

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit  

Disclaimer 

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.